CMLVAXb2a2-25

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameCMLVAXb2a2-25
Drug Alias NameP210-B2A2 derived peptide vaccine (sc, CML)
ClassificationVaccines > Application > Therapeutic vaccineVaccines > Development/production technology > Synthetic peptide vaccine
Mechanisms of ActionBcr-Abl tyrosine kinase modulators
TargetsBcr-Abl tyrosine kinase
Therapy Area/IndicationsLeukemia, Myelogenous, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesLeipzig University
China Registration ClassN/A

Develop Information

Active CompaniesLeipzig University
Inactive CompaniesN/A
Active IndicationsLeukemia, Myelogenous, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A